Clinical trial
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
NCT00445042 · The Methodist Hospital Research Institute, Other · Completed
Key facts
| NCT number | NCT00445042 |
|---|---|
| Title | Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer |
| Official title | A Phase II Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma |
| Lead sponsor | The Methodist Hospital Research Institute, Other |
| Collaborators | Bayer Industry Amgen |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | Sorafenib |
| Enrollment | 71 |
| Start date | Nov 1, 2005 |
| Primary completion | Sep 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Mar 8, 2007 |
| Last update posted | Mar 17, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: